Takemura, Ryo

写真a

Affiliation

School of Medicine, Clinical and Translational Research Center (Shinanomachi)

Position

Project Associate Professor (Non-tenured)

Academic Degrees 【 Display / hide

  • 博士(医学), Chiba University, Coursework, 2018.09

 

Papers 【 Display / hide

  • A double-blind, randomized, placebo-controlled trial of heat-killed pediococcus acidilactici k15 for prevention of respiratory tract infections among preschool children

    Hishiki H., Kawashima T., Tsuji N.M., Ikari N., Takemura R., Kido H., Shimojo N.

    Nutrients (Nutrients)  12 ( 7 ) 1 - 10 2020.07

     View Summary

    © 2020 by the authors. Although some probiotic bacteria have been reported to prevent infections in children, there are few well-designed double-blind studies. Here we evaluated the effects of a probiotic strain of lactic acid bacteria (LAB), Pediococcus acidilactici K15, on viral respiratory tract infections in preschool children. A four-month, randomized, double-blind, placebo-controlled study was performed in 172 healthy children aged 3 to 6 years. Subjects were administered dextrin alone or dextrin including heat-killed K15 (5 × 1010 bacteria). The number of febrile days was the primary outcome. The number of absent days from preschools and the influenza incidence were secondary outcomes. Secretory IgA (sIgA) concentrations in saliva were measured as an exploratory outcome. The primary and secondary outcomes were not significantly different between both groups. Analyses in children with little intake of fermented foods including LAB showed that the duration of a fever significantly decreased by K15 intake. The salivary sIgA level in the K15 group was maintained significantly higher than it was in the placebo group. The effects of K15 on preventing viral respiratory tract infections were not observed without the restriction of fermented foods intake. However, K15 supported anti-infectious immune systems in children who took less fermented foods and the maintenance of salivary sIgA levels in all subjects.

  • Usefulness of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma

    Yokose T., Kitago M., Matsusaka Y., Masugi Y., Shinoda M., Yagi H., Abe Y., Oshima G., Hori S., Endo Y., Toyama K., Iwabuchi Y., Takemura R., Ishii R., Nakahara T., Okuda S., Jinzaki M., Kitagawa Y.

    Cancer Medicine (Cancer Medicine)  9 ( 12 ) 4059 - 4068 2020.06

     View Summary

    © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Background: The Response Evaluation Criteria in Solid Tumors (RECIST) for computed tomography (CT) is preoperatively used to evaluate therapeutic effects. However, it does not reflect the pathological treatment response (PTR) of pancreatic ductal adenocarcinoma (PDAC). The Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) for positron emission tomography (PET)/CT is effective in other cancers. This study aimed to confirm the usefulness of PERCIST and the prognostic utility of PET/CT for PDAC. Methods: Forty-two consecutive patients with PDAC who underwent neoadjuvant therapy (NAT) and pancreatectomy at our institution between 2014 and 2018 were retrospectively analyzed. We evaluated the treatment response and prognostic significance of PET/CT parameters and other clinicopathological factors. Results: Twenty-two patients who underwent PET/CT both before and after NAT with the same protocol were included. RECIST revealed stable disease and partial response in 20 and 2 cases, respectively. PERCIST revealed stable metabolic disease, partial metabolic response, and complete metabolic response in 8, 9, and 5 cases, respectively. The PTR was G3, G2, and G1 in 8, 12, and 2 cases, respectively. For comparing the concordance rates between PTR and each parameter, PERCIST (72.7% [16/22]) was significantly superior to RECIST (36.4% [8/22]) (P =.017). The area under the curve survival values of PET/CT parameters were 0.777 for metabolic tumor volume (MTV), 0.500 for maximum standardized uptake value, 0.554 for peak standardized uptake value corrected for lean body mass, and 0.634 for total lesion glycolysis. A 50% cut-off value for the MTV reduction rate yielded the largest difference in survival between responders and nonresponders. On multivariate analysis, MTV reduction rates < 50% were independent predictors for relapse-free survival (hazard ratio [HR], 3.92; P =.044) and overall survival (HR, 14.08; P =.023). Conclusions: PERCIST was more accurate in determining NAT’s therapeutic effects for PDAC than RECIST. MTV reduction rates were independent prognostic factors for PDAC.

  • Minimally invasive oesophagectomy with extended lymph node dissection and thoracic duct resection for early-stage oesophageal squamous cell carcinoma

    Matsuda S., Kawakubo H., Takeuchi H., Hayashi M., Mayanagi S., Takemura R., Irino T., Fukuda K., Nakamura R., Wada N., Kitagawa Y.

    British Journal of Surgery (British Journal of Surgery)  107 ( 6 ) 705 - 711 2020.05

    ISSN  00071323

     View Summary

    © 2020 BJS Society Ltd Published by John Wiley & Sons Ltd Background: Oesophageal squamous cell carcinoma is an aggressive disease owing to early and widespread lymph node metastases. Multimodal therapy and radical surgery may improve prognosis. Few studies have investigated the efficacy of radical lymph node and thoracic duct resection. Methods: Patients with oesophageal squamous cell carcinoma who underwent transthoracic minimally invasive oesophagectomy (TMIE) for cancer at Keio University Hospital between January 2004 and December 2016 were selected. Between 2004 and 2008, TMIE was performed in the lateral decubitus position without thoracic duct resection (standard TMIE). From 2009 onwards, TMIE with extended lymph node and thoracic duct resection was introduced (extended TMIE). Demographics, co-morbidity, number of retrieved lymph nodes, pathology, postoperative complications and recurrence-free survival (RFS) were compared between groups. Results: Forty-four patients underwent standard TMIE and 191 extended TMIE. There were no significant differences in clinical and pathological tumour stage or postoperative complications. The extended-TMIE group had more lymph nodes removed at nodal stations 106recL and 112. Among patients with cT1 N0 disease, RFS was better in the extended-TMIE group (P < 0·001), whereas there was no difference in RFS between groups in patients with advanced disease. Conclusion: Extended TMIE including thoracic duct resection increased the number of lymph nodes retrieved and was associated with improved survival in patients with cT1 N0 oesophageal squamous cell carcinoma.

  • Loss of consciousness at ictus and/or poor World Federation of Neurosurgical Societies grade on admission reflects the impact of EBI and predicts poor outcome in patients with SAH

    Takahashi S., Akiyama T., Horiguchi T., Miwa T., Takemura R., Yoshida K.

    Surgical Neurology International (Surgical Neurology International)  11 ( 40 )  2020.03

     View Summary

    © 2020 Scientific Scholar. All rights reserved. Background: There are many scores and markers that predict poor outcome in patients with subarachnoid hemorrhage (SAH). However, parameters that can predict outcomes in patients with SAH with high specificity and sensitivity, which can be identified in the early postictal state and utilized as a clinical marker of early brain injury (EBI) have not been identified so far. Methods: Thirty-nine patients with SAH due to a saccular intracranial aneurysm rupture were reviewed. We retrospectively analyzed the relationships between patients' baseline characteristics and patients' outcomes to identify parameters that could predict patient outcomes in the early postictal state. Results: In the univariate analysis, older age (>65), loss of consciousness (LOC) at ictus, poor initial World Federation of Neurosurgical Societies (WFNS) grade (3-5), and delayed cerebral ischemia (DCI) were associated with poor outcome (GOS 1-3). Statistical analyses revealed that combined LOC at ictus and/or poor initial WFNS grade (3-5) was a more powerful surrogate marker of outcome (OR 15.2 [95% CI 3.1-75.5]) than either LOC at ictus or the poor initial WFNS grade (3-5) alone. Multivariate logistic regression analyses revealed that older age, combined LOC at ictus and/or poor initial WFNS grade, and DCI were independently associated with poor outcome. Conclusion: Combined LOC at ictus and/or poor initial WFNS grade (3-5) reflects the impact of EBI and was a useful surrogate marker of poor prognosis in SAH patients, independent of patients' age and state of DCI.

  • Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma

    Kanogawa N., Ogasawara S., Ooka Y., Inoue M., Wakamatsu T., Yokoyama M., Maruta S., Unozawa H., Iwanaga T., Sakuma T., Fujita N., Koroki K., Kanzaki H., Maeda T., Kobayashi K., Kiyono S., Nakamura M., Kondo T., Saito T., Motoyama T., Suzuki E., Nakamoto S., Tawada A., Chiba T., Arai M., Kanda T., Maruyama H., Kato J., Takemura R., Nozaki-Taguchi N., Shiroh I., Yokosuka O., Kato N.

    JGH Open (JGH Open)   2020

     View Summary

    © 2020 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. Background and Aim: Standardization of the sedation protocol during radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) is needed. This randomized, single-blind, investigator-initiated trial compared clinical outcomes during and after RFA using propofol and midazolam, respectively, in patients with HCC. Methods: Few- and small-nodule HCC patients (≤3 nodules and ≤3 cm) were randomly assigned to either propofol or midazolam. Patient satisfaction was assessed using a 100-mm visual analog scale (VAS) (1 mm = not at all satisfied, 100 mm = completely satisfied). Sedation recovery rates 1, 2, 3, and 4 h after RFA were evaluated based on Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores; full recovery was defined as a MOAA/S score of 5. Results: Between July 2013 and September 2017, 143 patients with HCC were enrolled, and 135 patients were randomly assigned to the treatment group. Compared with midazolam, propofol exhibited similar median procedural satisfaction (propofol: 73.1 mm, midazolam: 76.9 mm, P = 0.574). Recovery rates 1 and 2 h after RFA were higher in the propofol group than in the midazolam group. Meanwhile, recovery rates observed 3 and 4 h after RFA were similar in the two groups. The safety profiles during and after RFA were almost identical in the two groups. Conclusion: Patient satisfaction was almost identical in patients receiving propofol and midazolam sedation during RFA. Propofol sedation resulted in reduced recovery time compared with midazolam sedation in patients with HCC. The safety profiles of both propofol and midazolam sedation during and after RFA were acceptable.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

Presentations 【 Display / hide

  • 臨床研究データセンターにおけるデータマネジメント上の不適正事例

    竹村 亮

    第38回日本臨床学会学術総会 (神奈川県横浜市) , 

    2017.12

    Poster presentation, 日本臨床薬理学会

  • 千葉大学医学部附属病院における臨床研究の品質確保への取り組み実績

    TAKEMURA Ryo

    第37回日本臨床薬理学会学術総会 (鳥取県米子市) , 

    2016.12

    Poster presentation, 日本臨床薬理学会

  • Evaluation of variations obtained by the WholeGenome Sequencing of using the short read.

    Ryo Takemura, Terue Kitahara, Akihiro Sekine

    日本人類遺伝学会第60回大会 (東京都) , 

    2015.10

    Poster presentation, 日本人類遺伝学会

  • Normalized logistic-based rank transformation for QTL mapping methods.

    K. Shibata, R. Takemura, N. Kamatani.

    ASHG Annual Meeting 2005 (Salt Lake City, USA) , 

    2005.10

    Poster presentation, American society of Human Genetics

  • The determinant of haplotype frequency matrix can evaluate the Linkage Disequilibrium between multi-allelic loci.

    R. Takemura, S. Kamitsuji, N. Kamatani.

    ASHG Annual Meeting 2005 (Salt Lake City, USA) , 

    2005.10

    Poster presentation, American society of Human Genetics

display all >>

 

Courses Taught 【 Display / hide

  • DESIGN AND ANALYSIS OF CLINICAL TRIALS

    2024

  • BIOSTATISTICS AND MEDICAL INFORMATICS

    2024

  • DESIGN AND ANALYSIS OF CLINICAL TRIALS

    2023

  • BIOSTATISTICS AND MEDICAL INFORMATICS

    2023

  • DESIGN AND ANALYSIS OF CLINICAL TRIALS

    2022

display all >>